Evaluating a Blood Test and Voice Analysis to Improve Dementia Diagnosis in Adults with Cognitive Complaints
Led by Monash University · Updated on 2026-10-08
1000
Participants Needed
2
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether a blood test measuring Neurofilament light chain NfL protein levels can help diagnose dementia in people presenting with cognitive complaints within a single healthcare network. The study addresses challenges in current dementia diagnosis, such as missed subtle changes, cultural and language barriers, and limited access to advanced brain imaging, especially in diverse and regional populations. The goal is to develop accessible diagnostic pathways that improve timely and accurate dementia diagnosis.
Participants will have a one-time blood draw and speech test to measure brain protein levels and analyze voice acoustics. A follow-up at 12 months includes repeated speech tests and phone-based questionnaires and cognitive assessments. An optional genetic test using a saliva sample sent from home is available for those at risk of genetic dementia. These new technologies aim to create cost-effective and widely accessible diagnostic tools.
During the study, participants undergo initial blood and speech testing, then are followed up at one year with phone assessments and repeated speech analysis. Researchers will track changes in speech and language processing alongside NfL levels. The study measures baseline NfL protein and changes in speech and language over time. This approach aims to shorten diagnosis time, increase certainty, and improve access to care and future therapies for people with dementia.
CONDITIONS
Brief Title
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
Research Team
P
Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
S
Svetlana Ivanic, BSc(Hons)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients of any age presenting to Eastern Health services with cognitive complaints or possible neurodegenerative disorders
You will not qualify if you...
Expected prognosis less than 12 months
No cognitive complaints
Patients not receiving care within the Eastern Health network
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Initial Testing
Duration - 1 day
Participants undergo a single blood draw and speech test to measure brain protein levels and voice acoustics.
1 visit (in-person)
Follow-up
Duration - 12 months
Participants complete speech tests again and answer questionnaires and cognitive scales over the phone 12 months after initial testing. Optional genetic testing via a saliva sample may be completed at home.
1 phone visit
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
100-Year Human Aging Study Observing Multi-System Health to Predict Mortality and Aging Outcomes
Trial of the 5-Cog Assessment to Detect Cognitive Impairment and Improve Dementia Care in Older Adults with Cognitive Concerns in Primary Care
Evaluating an AI-Supported Behavioral Sleep Program for Adults with Mild Cognitive Impairment and Dementia Compared to Usual Care
Using a Digital Life Story Application to Support Person-Centered Care for Older Adults with Dementia Healthcare Professionals Views
Combination of Sleep Promotion and Cognitive Training to Improve Brain Function in Older Adults After ICU Stay
Evaluating Multifocal Non-Invasive Brain Stimulation and Cognitive Training to Improve Symptoms in Mild Cognitive Impairment and Early Dementia
Phase 3 Study Evaluating Single-Dose Nexiguran Ziclumeran for Hereditary Transthyretin Amyloidosis with Polyneuropathy ATTRv-PN
Pilot Study of a 12-Week Robot-Assisted Activity Program to Increase Physical Activity in People with Dementia and Their Caregivers
A Phase IIIII Study Testing Remternetug to Prevent or Slow Alzheimers Disease Progression in Adults with Genetic Risk
Evaluating Annual Intravenous Donanemab in Adults Who Completed AACM Study for Alzheimer Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Neurofilament light chain and voice acoustics in dementia diagnosis (NAVAIDD): Protocol for a cohort study assessing the real-world diagnostic utility of blood and digital biomarkers in clinical settings.
Svetlana Ivanic, Adam P Vogel, Pratishtha Chatterjee...